CIK 0001372514
- Non-accelerated filer
- Smaller reporting company
KIORA PHARMACEUTICALS INC
Sign in to watch- Tickers
- KPRX KPHMW
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 980443284
- Phone
- +1 858-224-9600
- Business address
- 169 SAXONY RD., SUITE 212, ENCINITAS, CA, 92024
- Former names
- EYEGATE PHARMACEUTICALS INC
Securities
- KPRX Common Stock Nasdaq
- KPHMW Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 73 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-21 | BALLAND THOMAS Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-21 | TYLE PRAVEEN Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-21 | CHANEY PAUL G Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-21 | GOLDBERG MORTON Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-21 | MALFROY-CAMINE BERNARD Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-14 | Romano Sarah Interim CFO | Purchase | +20,000 | 22,500 | ||
| 2017-06-14 | Romano Sarah Interim CFO | Purchase · Warrants (right to buy) | +20,000 | 20,000 | ||
| 2017-06-14 | FROM STEPHEN President and CEO | Purchase | +60,000 | 259,965 | ||
| 2017-06-14 | FROM STEPHEN President and CEO | Purchase · Warrants (right to buy) | +60,000 | 60,000 | ||
| 2017-06-02 | CHANEY PAUL G Director | Exercise or conversion | +17,570 | $0.65 | $11K | 41,229 |
| 2017-06-02 | CHANEY PAUL G Director | Exercise or conversion · Stock Option (right to buy) | −17,570 | 0 | ||
| 2017-05-18 | MANZO MICHAEL P. Vice President of Engineering | Grant or award · Stock Option (right to buy) | +8,000 | 8,000 | ||
| 2017-05-18 | FROM STEPHEN President and CEO | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2017-05-15 | MANZO MICHAEL P. Vice President of Engineering | Exercise or conversion | +7,285 | $0.65 | $5K | 19,546 |
| 2017-05-15 | MANZO MICHAEL P. Vice President of Engineering | Exercise or conversion · Stock Option (right to buy) | −7,285 | 0 | ||
| 2017-03-13 | Ventech Capital II 10% owner | Sale | −4,419 | $2.80 | $12K | 1,431,814 |
| 2017-03-07 | Wirostko Barbara Chief Medical Officer | Grant or award | +8,700 | $2.83 | $25K | 217,842 |
| 2017-03-06 | GOLDBERG MORTON Director | Sale | −8,919 | $3.00 | $27K | 9,441 |
| 2017-02-28 | Wirostko Barbara Chief Medical Officer | Grant or award | +54,200 | $2.59 | $140K | 209,142 |
| 2017-02-28 | Wirostko Barbara Chief Medical Officer | Grant or award | +41,700 | $2.60 | $108K | 41,700 |
Page 23 of 24 · 468 trades